Mnemo Therapeutics
Aurélie Le Gallo Dumas has worked in a variety of roles in the Human Resources field since 2014. Aurélie began their career as an Equipière Polyvalente at McDonald's Corporation in 2014, followed by a Technicien Stagiaire role at Geofundaciones Bogotà in 2015. In 2016, they took on an Assistant and Recruitment Consultant role at Manpower, followed by an HR in Diversity and Professional Equality role at EDF in 2017. In 2018, Aurélie worked as an HR Generalist at both Saint Laurent and Getty Images. From 2020 to 2022, they worked as an HR Generalist at Balmain, where they were responsible for personnel administration, payroll, and talent and acquisition. Currently, they are an HR Generalist at Mnemo Therapeutics, where they are responsible for personnel administration, payroll, and recruitment.
Aurélie Le Gallo Dumas obtained their Baccalauréat in scientific studies from Lycée Marie Curie in 2012. Aurélie then attended Camille Vernet, where they studied ECS in preparation for Grandes Ecoles de Commerce, with an option in Mathematics, from 2012 to 2014. In 2017, they attended the University of Exeter to study Management. Aurélie also obtained their TOEFL certification in January 2017, with a score of 104/120. Finally, they obtained their Master's degree in Gestion des ressources humaines / administration du personnel from KEDGE Business School in 2018.
This person is not in any teams
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.